Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;21(11):1118-1131.
doi: 10.6004/jnccn.2023.0057.

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Andrew D Zelenetz  1 , Leo I Gordon  2 , Jeremy S Abramson  3 , Ranjana H Advani  4 , Babis Andreadis  5 , Nancy L Bartlett  6 , L Elizabeth Budde  7 , Paolo F Caimi  8 , Julie E Chang  9 , Beth Christian  10 , Sven DeVos  11 , Bhagirathbhai Dholaria  12 , Luis E Fayad  13 , Thomas M Habermann  14 , Muhammad Saad Hamid  15 , Francisco Hernandez-Ilizaliturri  16 , Boyu Hu  17 , Mark S Kaminski  18 , Yasmin Karimi  18 , Christopher R Kelsey  19 , Rebecca King  14 , Susan Krivacic  20 , Ann S LaCasce  21 , Megan Lim  1 , Marcus Messmer  22 , Mayur Narkhede  23 , Rachel Rabinovitch  24 , Praveen Ramakrishnan  25 , Erin Reid  26 , Kenneth B Roberts  27 , Hayder Saeed  28 , Stephen D Smith  29 , Jakub Svoboda  30 , Lode J Swinnen  31 , Joseph Tuscano  32 , Julie M Vose  33 , Mary A Dwyer  34 , Hema Sundar  34
Affiliations

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Andrew D Zelenetz et al. J Natl Compr Canc Netw. 2023 Nov.

Abstract

Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

PubMed Disclaimer

Publication types

LinkOut - more resources